NDAORALTABLET
Approved
May 2004
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
3/8 — Basic
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIFAXAN (rifaximin) is an oral rifamycin-class antibacterial approved in 2004 for treating traveler's diarrhea and hepatic encephalopathy. It acts as a non-systemic antibiotic with local gut activity, minimizing systemic absorption and drug interactions. The drug targets enteric bacterial infections and is now in peak commercial lifecycle.
Peak3.3 years to LOE
Peak-stage product with high competitive pressure (8/10) suggests mature brand requiring defensive commercial strategies and optimization-focused team models.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Rifaximin 200 mg Plus Oral Rehydration vs Oral Rehydration Alone in Children With Acute Diarrhea
Started Feb 2026
54 enrolled
DiarrheaGastroenteritisBacterial Infection
Rifaximin SSD in Dementia Trial
Started Dec 2024
20 enrolled
Dementia Alzheimer TypeDementia Associated With Cerebrovascular Disease
Rifaximin for the Secondary Prevention of Recurrent Pouchitis
Started Jul 2024
16 enrolled
Pouchitis
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
Started Feb 2024
34 enrolled
Small Intestinal Bacterial Overgrowth
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Started Aug 2022
466 enrolled
Hepatic Encephalopathy
Worked on XIFAXAN at Bausch Health? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.